Overview#
Oppenheimer has reiterated its Outperform rating for Compass Pathways (NASDAQ:CMPS) and set a price target of $20.00. The stock has seen a significant increase of 129% over the past year, currently trading at $9.69, close to its 52-week high of $10.21. However, some data suggests that the stock may be overvalued at this time.
FDA Review and Treatment Development#
The firm believes that the U.S. Food and Drug Administration (FDA) granting a Complex Novel Product Verification, along with a rolling New Drug Application (NDA) review, strengthens the timeline for the launch of COMP360. This treatment is based on psilocybin, a compound found in certain mushrooms, and is aimed at helping individuals with treatment-resistant depression.
Previously, Compass Pathways planned to submit its NDA by the end of 2026 after completing a Phase 3 study. Oppenheimer now anticipates that the launch could happen by the end of 2026, provided that the NDA submission includes data on the treatment's effectiveness over time.
Strategic Collaborations#
Oppenheimer recently engaged with Compass Pathways' management, who discussed their partnership with Osmind, which is focused on preparing psychiatric clinics for the potential delivery of psychedelic treatments. This collaboration aims to identify the necessary operational and clinical requirements for the rollout of COMP360, indicating a proactive approach by Compass Pathways to enhance its treatment offerings.
Market Sentiment#
The sentiment around psychedelics is improving, with other firms also expressing positive views on Compass Pathways. Morgan Stanley has reiterated an Overweight rating with a price target of $16.00, while B.Riley has initiated coverage with a Buy rating and a target of $17.00. These ratings reflect optimism about COMP360 potentially becoming the first FDA-approved oral psychedelic drug for treatment-resistant depression.